Amgen bids $167M to buy drug discovery shop Nuevolution

Amgen has offered $167 million (€150 million) to buy Nuevolution. The takeover will give Amgen control of a drug discovery platform that landed Nuevolution deals with leading companies plus a pipeline of early-stage cancer and inflammation programs. Denmark’s Nuevolution made a name for itself over the past decade through a series of deals with major drugmakers including GlaxoSmithKline.
Read more...

;